Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it
Yuanyuan Wang, Jiyuan Chen, Zhengjie Wu, et al.
British Journal of Pharmacology (2020) Vol. 178, Iss. 2, pp. 239-261
Open Access | Times Cited: 82

Showing 51-75 of 82 citing articles:

The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
Rebecka Hellsten, Anna Stiehm, Macarena Palominos, et al.
Translational Oncology (2022) Vol. 24, pp. 101495-101495
Open Access | Times Cited: 5
Molecular Insight into Prostate Cancer: Preventive Role of Selective Bioactive Molecules
Mohd Jameel, Homa Fatma, Людмила Надточий, et al.
Life (2023) Vol. 13, Iss. 10, pp. 1976-1976
Open Access | Times Cited: 2
CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression.
Xi Chen, Haopeng Li, Chengdang Xu, et al.
PubMed (2023) Vol. 13, Iss. 9, pp. 4003-4020
Closed Access | Times Cited: 2
What should be the future direction of development in the field of prostate cancer with lung metastasis?
Zhi‐Guang Huang, Yi Chen, Tong Wu, et al.
World Journal of Clinical Oncology (2023) Vol. 14, Iss. 10, pp. 420-439
Open Access | Times Cited: 2
A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
Yan Li, Ya Chu, Guangjiang Shi, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 11, pp. 4165-4179
Open Access | Times Cited: 4
Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review)
Hongyuan Wan, Yanyan Feng, Jun‐Jie Wu, et al.
Molecular Medicine Reports (2022) Vol. 26, Iss. 3
Open Access | Times Cited: 3
Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer
Zhengyang Han, Ujjwal Rimal, Prabesh Khatiwada, et al.
Endocrinology (2022) Vol. 164, Iss. 1
Open Access | Times Cited: 3
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer
Chengfei Liu, Bo Chen, Pengfei Xu, et al.
Research Square (Research Square) (2024)
Open Access
Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells
Chao Cai, Qinwei Liu, Haoran Shan, et al.
Genetic Testing and Molecular Biomarkers (2024) Vol. 28, Iss. 6, pp. 243-256
Closed Access
Synergistic PTEN Restoration and CXCR2 Depletion with a Bone-Targeting Lipid Nanocomposite Inhibits Drug-Resistant CRPC Metastasis to Bone
Luyao Gong, Jiyuan Chen, G. Song, et al.
(2024)
Closed Access
Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer.
Haleema Azam, Colin Veale, K Zitzmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Potential drug targets for prostate cancer ： A mendelian randomization study and application for target-derived drug design
Long Cheng, Shu Gan, Peijian Huang, et al.
Research Square (Research Square) (2024)
Open Access
PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway
Jing Hu, Jing Zhang, Bo Han, et al.
Neoplasia (2024) Vol. 57, pp. 101047-101047
Open Access
Therapeutic potential of targeting AKR1C2 in the treatment of prostate cancer
Mingyi Nie, Tian Li, Peng Liu, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access
Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration‐Resistant Prostate Cancer
Yixian Liu, Yongji He, Xiaohui Qi, et al.
Clinical Pharmacology in Drug Development (2024)
Open Access
Metformin in Overcoming Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Kendall Simpson, Derek B. Allison, Daheng He, et al.
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 392, Iss. 1, pp. 100034-100034
Open Access
MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway
Shengfeng Zheng, Zhe Hong, Yao Tan, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access
NRG1 secreted by cancer-associated fibroblasts contributes to enzalutamide resistance in prostate cancer cells
Chunyu Wang, Hongwen Cao, Peng Sun, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 10, pp. 4830-4840
Closed Access
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
Piotr Białas, Tamae Kobayashi, Rebecka Hellsten, et al.
The Prostate (2024)
Open Access
S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance
Saptadwipa Ganguly, Ravshan Burikhanov, Vitaliy M. Sviripa, et al.
International Journal of Biological Sciences (2024) Vol. 21, Iss. 2, pp. 454-472
Closed Access
Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer
Haleema Azam, Colin Veale, K Zitzmann, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0309491-e0309491
Open Access
Combined Blockade of Lipid Uptake and Synthesis by CD36 Inhibitor and SCD1 siRNA Is Beneficial for the Treatment of Refractory Prostate Cancer
Jiyuan Chen, Xiaoyan Yu, Gang Yang, et al.
Advanced Science (2024)
Open Access
A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer
Lili Wang, Yun Peng, Shiqiang Dong, et al.
Annals of Translational Medicine (2021) Vol. 9, Iss. 24, pp. 1782-1782
Open Access | Times Cited: 3
Establishment and evaluation of ectopic and orthotopic prostate cancer models using cell sheet technology
Dongliang Zhang, Ying Wang, Lei Liu, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 2
CYP19A1 Is Regulated by BRD4 and Suppresses Castration-resistant Prostate Cancer Cell Invasion and Proliferation by Decreasing AR Expression
Xi Chen, Chengdang Xu, Xinan Wang, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 1

Scroll to top